Pay in 4 interest-free payments of $6.32 Learn more
Ships within 48 hours · Estimated delivery Aug 24 - Aug 29
L.SmithA
Does not require commercial insurance
Released as a repair signal when collagen is damaged
Following our data for CT-388, this is the second positive readout in less than three months from our growing metabolic pipeline, which includes both oral and injectable options to address patients' needs across a spectrum of related diseases." CT-996 was well tolerated, with mostly mild or moderate gastrointestinal-related adverse events, consistent with the safety profile of the incretin drug class
US$ 22.84
US$ 26.62
US$ 25.50
US$ 29.86
US$ 29.24
